| 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management F Gomollón, A Dignass, V Annese, H Tilg, G Van Assche, JO Lindsay, ... Journal of Crohn's and Colitis 11 (1), 3-25, 2017 | 2172 | 2017 |
| Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer … F Magro, P Gionchetti, R Eliakim, S Ardizzone, A Armuzzi, ... Journal of Crohn's and Colitis 11 (6), 649-670, 2017 | 1676 | 2017 |
| ECCO guidelines on therapeutics in Crohn's disease: medical treatment J Torres, S Bonovas, G Doherty, T Kucharzik, JP Gisbert, T Raine, ... Journal of Crohn's and Colitis 14 (1), 4-22, 2020 | 1050 | 2020 |
| Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease JF Rahier, F Magro, C Abreu, A Armuzzi, S Ben-Horin, Y Chowers, ... Journal of Crohn's and Colitis 8 (6), 443-468, 2014 | 1007 | 2014 |
| Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial JF Colombel, R Panaccione, P Bossuyt, M Lukas, F Baert, T Vaňásek, ... The Lancet 390 (10114), 2779-2789, 2017 | 819 | 2017 |
| The molecular classification of the clinical manifestations of Crohn's disease T Ahmad, A Armuzzi, M Bunce, K Mulcahy–Hawes, SE Marshall, ... Gastroenterology 122 (4), 854-866, 2002 | 786 | 2002 |
| Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis MA Zocco, LZ Dal Verme, F Cremonini, AC Piscaglia, EC Nista, ... Alimentary pharmacology & therapeutics 23 (11), 1567-1574, 2006 | 655 | 2006 |
| Effect of Different Probiotic Preparations on Anti-Helicobacter PyloriTherapy-Related Side Effects: A Parallel Group, Triple Blind, Placebo-Controlled Study F Cremonini, S Di Caro, M Covino, A Armuzzi, M Gabrielli, L Santarelli, ... Official journal of the American College of Gastroenterology| ACG 97 (11 …, 2002 | 536 | 2002 |
| Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn’s Disease G Monteleone, MF Neurath, S Ardizzone, A Di Sabatino, MC Fantini, ... New England Journal of Medicine 372 (12), 1104-1113, 2015 | 475 | 2015 |
| ECCO guidelines on therapeutics in Crohn’s disease: surgical treatment M Adamina, S Bonovas, T Raine, A Spinelli, J Warusavitarne, A Armuzzi, ... Journal of Crohn's and Colitis 14 (2), 155-168, 2020 | 446 | 2020 |
| Advanced age is an independent risk factor for severe infections and mortality in patients given anti–tumor necrosis factor therapy for inflammatory bowel disease M Cottone, A Kohn, M Daperno, A Armuzzi, L Guidi, R D'Inca, F Bossa, ... Clinical Gastroenterology and Hepatology 9 (1), 30-35, 2011 | 373 | 2011 |
| European Crohn’s and Colitis Organisation [ECCO]. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis … F Magro, P Gionchetti, R Eliakim, S Ardizzone, A Armuzzi, ... J Crohns Colitis 11 (6), 649-670, 2017 | 365 | 2017 |
| Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study C Bezzio, S Saibeni, A Variola, M Allocca, A Massari, V Gerardi, V Casini, ... Gut 69 (7), 1213-1217, 2020 | 345 | 2020 |
| NOD2/CARD15 gene polymorphisms and Crohn's disease in the Chinese population RWL Leong, A Armuzzi, T Ahmad, ML Wong, P Tse, DP Jewell, JJY Sung Alimentary pharmacology & therapeutics 17 (12), 1465-1470, 2003 | 312 | 2003 |
| Water supplementation enhances the effect of high-fiber diet on stool frequency and laxative consumption in adult patients with functional constipation. M Anti, G Pignataro, A Armuzzi, A Valenti, E Iascone, R Marmo, ... Hepato-gastroenterology 45 (21), 727-732, 1998 | 301 | 1998 |
| Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study A Armuzzi, F Cremonini, V Ojetti, F Bartolozzi, F Canducci, M Candelli, ... Digestion 63 (1), 1-7, 2001 | 294 | 2001 |
| Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn’s disease WJ Sandborn, BG Feagan, EV Loftus Jr, L Peyrin-Biroulet, G Van Assche, ... Gastroenterology 158 (8), 2123-2138. e8, 2020 | 222 | 2020 |
| Infliximab in severe ulcerative colitis: short‐term results of different infusion regimens and long‐term follow‐up A Kohn, M Daperno, A Armuzzi, M Cappello, L Biancone, A Orlando, ... Alimentary pharmacology & therapeutics 26 (5), 747-756, 2007 | 203 | 2007 |
| Genotype-phenotype analysis of the Crohn's disease susceptibility haplotype on chromosome 5q31 jewell armuzzi, ahmad gut 52 (8), 1133-1139, 2003 | 196* | 2003 |
| Mapping the HLA association in Behçet's disease: a role for tumor necrosis factor polymorphisms? T Ahmad, GR Wallace, T James, M Neville, M Bunce, K Mulcahy‐Hawes, ... Arthritis & Rheumatism 48 (3), 807-813, 2003 | 194 | 2003 |
Antonio GasbarriniProfessor of Gastroenterology, Catholic University, Gemelli Hospital, Rome, ItalyVerified email at iol.it
